share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K:重大事件
美股SEC公告 ·  09/13 16:28

Moomoo AI 已提取核心訊息

On September 12, 2024, Exicure, Inc., a biotechnology company based in Chicago, entered into agreements to convert debt into equity with two of its promissory note holders. The company reached a deal with DGP Co., Ltd., its largest shareholder, to issue 237,233 shares in exchange for the full satisfaction of a $700,000 promissory note, including accrued interest. The conversion price was set at $3.00 per share. Additionally, an agreement was made with an individual note holder to issue 101,991 shares for the full satisfaction of a $300,000 promissory note, also at a conversion price of $3.00 per share. These shares will be issued unregistered under the Securities Act of 1933, in a private transaction exempt from registration requirements. In a separate event on September 13, 2024, Exicure announced that it had regained compliance with Nasdaq's minimum bid price requirement, maintaining its listing on the exchange.
On September 12, 2024, Exicure, Inc., a biotechnology company based in Chicago, entered into agreements to convert debt into equity with two of its promissory note holders. The company reached a deal with DGP Co., Ltd., its largest shareholder, to issue 237,233 shares in exchange for the full satisfaction of a $700,000 promissory note, including accrued interest. The conversion price was set at $3.00 per share. Additionally, an agreement was made with an individual note holder to issue 101,991 shares for the full satisfaction of a $300,000 promissory note, also at a conversion price of $3.00 per share. These shares will be issued unregistered under the Securities Act of 1933, in a private transaction exempt from registration requirements. In a separate event on September 13, 2024, Exicure announced that it had regained compliance with Nasdaq's minimum bid price requirement, maintaining its listing on the exchange.
2024年9月12日,總部位於芝加哥的生物技術公司Exicure, Inc.與兩個其本票持有人簽訂協議,將債務轉換爲股權。該公司與其最大股東DGP Co., Ltd.達成協議,以發行237,233股股票交換全額償還70萬美元本票,包括應計利息。轉換價格爲每股3.00美元。此外,該公司還與個人本票持有人達成協議,以發行101,991股股票全額償還30萬美元本票,轉換價格同樣爲每股3.00美元。這些股票將以未註冊形式發行,根據1933年的證券法,在一個豁免註冊要求的私人交易中完成。在2024年9月13日的另一個事件中,Exicure宣佈已恢復納斯達克最低買盤價格要求的合規性,並維持在交易所的上市。
2024年9月12日,總部位於芝加哥的生物技術公司Exicure, Inc.與兩個其本票持有人簽訂協議,將債務轉換爲股權。該公司與其最大股東DGP Co., Ltd.達成協議,以發行237,233股股票交換全額償還70萬美元本票,包括應計利息。轉換價格爲每股3.00美元。此外,該公司還與個人本票持有人達成協議,以發行101,991股股票全額償還30萬美元本票,轉換價格同樣爲每股3.00美元。這些股票將以未註冊形式發行,根據1933年的證券法,在一個豁免註冊要求的私人交易中完成。在2024年9月13日的另一個事件中,Exicure宣佈已恢復納斯達克最低買盤價格要求的合規性,並維持在交易所的上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息